Dual CAR-T therapy targeting solid tumors: insights from intracerebroventricular delivery

In this webinar, Stephen J Bagley (Assistant Professor, University of Pennsylvania) will share rare Phase 1 data from a first-in-human trial using bivalent CAR-T cells targeting EGFR and IL-13Ra2, exploring how these therapies behave in the cerebrospinal fluid and CNS microenvironment.

What you will learn:

Pharmacokinetics & immune profiling
Understand how CAR-T cells distribute and persist in the CSF and CNS, with insights into immune activation and tumor microenvironment reshaping.

Dual targeting antigens
Learn the rationale behind dual targeting and see preclinical efficacy data supporting the bivalent CAR-T approach.

Clinical response patterns
Review case studies that highlight tumor behavior, imaging evolution, and response trajectories in treated patients. Plus, explore early repeat dosing protocols designed to improve CAR-T persistence and long-term response.

Overcoming solid tumor barriers
Gain strategies to address antigen heterogeneity, trafficking limitations, and immunosuppressive environments in CNS-targeted therapies.

Safety & dosing frameworks
Learn about dose-level guidance, neurotoxicity management, and updated grading models specific to CNS applications – including distinctions between TIAN and ICANS.

Manufacturing
Review workflows for successful manufacturing of dual antigen-targeting CAR-T cells.

Join the webinar to:

• Access rare Phase 1 clinical data from a novel ICV CAR-T trial
• Gain actionable strategies for your CAR-T pipeline
• Stay ahead in next-generation immunotherapy for solid tumors

Stephen J. Bagley

Assistant Professor of Medicine (Hematology-Oncology) at University of Pennsylvania

Dr. Stephen J. Bagley, MD, MSCE Assistant Professor of Medicine, University of Pennsylvania Section Chief of Neuro-Oncology | Clinical Director, Penn Brain Tumor Center Dr. Stephen Bagley is a leading neuro-oncologist and physician-scientist at the University of Pennsylvania, where he serves as Section Chief of Neuro-Oncology and Clinical Director of the Penn Brain Tumor Center. With board certification in hematology-oncology and advanced training in clinical epidemiology, Dr. Bagley has spearheaded transformative research in immunotherapeutic strategies for glioblastoma. His work is at the forefront of central nervous system (CNS) cell therapy, most recently leading a first-in-human clinical trial evaluating intracerebroventricular delivery of bivalent CAR T cells targeting EGFR and IL-13Rα2 in recurrent glioblastoma—published in Nature Medicine. His research focuses on translating cell-based immunotherapies to solid tumors, utilizing novel delivery mechanisms and biomarker-driven approaches to improve therapeutic response and durability. Dr. Bagley is widely published in top-tier journals and is recognized for shaping the evolving landscape of immunotherapy in neuro-oncology.

You have registered for this webinar

Watch now

SPEAKERS

Stephen J. Bagley

Assistant Professor of Medicine (Hematology-Oncology) at University of Pennsylvania

You might also like

Enhancing CAR-T efficacy for targeting lymphoma and solid tumors

Ruchi Patel

3 December 2024

Watch

Assessing CAR-T cell therapy in vitro using patient-derived glioblastoma organoids

Meghan Logun

5 November 2024

Watch

Commercialization of CAR-T therapy in New Zealand: clinical insights & scalable manufacturing

Tamara Laskowski, Laurence Cooper

12 August

Watch

Advancing TCR-based therapies: discovery, analysis, and QC of Ag-specific T cells targeting solid cancers

Marc Schuster, Marek Wieczorek

17 October 2024

Watch